| Literature DB >> 34966139 |
Dirkje de Blauw1, Andrea H L Bruning2, Katja C Wolthers3, Anne-Marie van Wermeskerken4, Maarten H Biezeveld5, Joanne G Wildenbeest1, Dasja Pajkrt1.
Abstract
Entities:
Mesh:
Year: 2022 PMID: 34966139 PMCID: PMC8920014 DOI: 10.1097/INF.0000000000003441
Source DB: PubMed Journal: Pediatr Infect Dis J ISSN: 0891-3668 Impact factor: 3.806
Demographics + Clinical Symptoms of Children With a Suspected Meningoencephalitis on Admission
| Demographic Characteristics, n (%) | Proven ME | Possible ME | No ME | ||
|---|---|---|---|---|---|
| Total | n = 432 (100.0) | ||||
| Male gender | 248 (57.4) | 35 (53.0) | 23 (61.0) | 190 (57.9) | |
| Age (days), median (IQR) | 45.5 (11.0–351.2) | 82.0 (17.0–876.5) | 55.0 (12.0–350.0) | 43.0 (9.0–312.0) | |
| Comorbidities | 106 (25.2) | 6 (9.4) | 10 (26.3) | 90 (28.3) | |
| Prematurity | 89/426 (20.9) | 6/89 | 9/89 | 74/89 | |
| Gestational age <28 weeks | 9/89 (10.1) | 1/6 (16.7) | 1/9 (11.1) | 7/74 (9.5) | |
| Gestational age between 28 and 32 weeks | 33/89 (37.1) | 4/6 (66.7) | 4/9 (44.4) | 25/74 (33.8) | |
| Gestational age between 32 and 37 weeks | 47/89 (52.8) | 1/6 (16.7) | 4/9 (44.4) | 42/74 (56.8) | |
| Clinical symptoms | |||||
| Fever | 253/400 (63.3) | 49/63 (77.8) | 21/31 (67.7) | 183/306 (59.8) | |
| Nausea | 96/364 (26.4) | 18/53 (34.0) | 9/27 (33.3) | 69/284 (24.3) | |
| Skin rash | 58/312 (22.8) | 15/53 (28.3) | 8/27 (29.6) | 35/232 (15.1) | |
| Petechia | 11/58 (19.0) | 4/53 (7.5) | 2/27 (7.4) | 5/232 (2.2) | |
| Diarrhea | 49/379 (12.9) | 9/56 (16.1) | 5/30 (16.7) | 35/293 (11.9) | |
| Neurological symptoms | |||||
| Irritability (age <2 years) | 158/314 (50.3) | 27/46 (58.7) | 18/28 (64.3) | 113/240 (47.1) | |
| Decreased consciousness (GCS ≤7) | 19/94 (20.2) | 5/20 (25.0) | 2/14 (14.3) | 12/60 (20.0) | |
| Meningeal irritation/neck stiffness | 44/220 (20.0) | 9/39 (23.1) | 5/19 (26.3) | 30/162 (18.5) | |
| Aphasia | 4/59 (6.8) | 2/4 (50.0) | 0/4 (0.0) | 2/4 (50.0) | |
| Ataxia | 6/55 (10.9) | 2/6 (33.3) | 1/6 (16.7) | 3/6 (50.0) | |
| Seizures | 48/407 (11.8) | 8/59 (13.6) | 4/33 (12.1) | 36/315 (11.4) | |
| Focal | 5/48 (10.4) | 1/5 (20.0) | 2/5 (40.0) | 2/5 (40.0) | |
| Generalized | 15/48 (31.3) | 2/15 (13.3) | 0/15 (0.0) | 13/15 (86.7) | |
| Status epilepticus | 8/48 (16.7) | 1/8 (12.5) | 0/8 (0.0) | 7/8 (87.5) | |
| Cranial nerve palsy | 10/128 (7.8) | 2/24 (8.3) | 1/15 (6.7) | 7/89 (7.9) | |
| N. III | 3/10 (30.0) | 1/3 (33.3) | 0/3 (0.0) | 2/3 (66.7) | |
| N. VI | 2/10 (20.0) | 0/2 (0.0) | 0/2 (0.0) | 2/2 (100.0) | |
| N. VII | 5/10 (50.0) | 1/5 (20.0) | 1/5 (20.0) | 3/5 (60.0) |
Data are obtained by a review of medical records and presented as n (%) or median (IQR). Decreased consciousness is defined as a GCS of ≤7.
GCS indicates Glasgow Coma Scale; ME, meningoencephalitis.
Etiology and Age Distribution of Children With a Proven and Possible Meningoencephalitis, n (%)
| Total Proven Meningoencephalitis (%) | 66/432 (15.3) | |
|---|---|---|
| Infectious meningoencephalitis | 61/66 (92.4) | |
| Bacterial meningoencephalitis | 17/61 (27.9) | |
|
| 4/17 (23.5) | |
|
| 2/17 (11.7) | |
|
| 4/17 (23.5) | |
| Other | 7/17 (41.2) | |
| Viral meningoencephalitis | 37/61 (60.7) | |
| Enterovirus | 25/37 (67.6) | |
| Adenovirus | 4/37 (10.8) | |
| Human parechovirus | 3/37 (8.1) | |
| VZV | 2/37 (5.4) | |
| HHV6 | 2/37 (5.4) | |
| HSV (type 1) | 1/37 (2.7) | |
| 2/61 (3.3) | ||
| No pathogen detected in CSF | 5/61 (8.2) | |
| Autoimmune encephalitis | 5/66 (7.6) | |
| ADEM | 2/5 (40.0) | |
| Anti-NMDA | 1/5 (20.0) | |
| Possible meningoencephalitis | 38 (8.8) | |
| Median age at diagnosis of | ||
| Bacterial meningoencephalitis (median days, IQR) | 99.0 (10.0–300.0) | |
| Viral meningoencephalitis (median days, IQR) | 29.0 (16.0–204.0) | |
| Autoimmune meningoencephalitis (median years, IQR) | 10.0 (9.0–14.0) | |
| Possible meningoencephalitis (median days, IQR) | 55.0 (12.0–350.0) |
Data are presented as n (%) and IQR.
Other is a grouped category of several bacterial pathogens that could only be identified once. The distinction between proven, possible and no meningoencephalitis was made based on the definitions described in the Methods section.
ADEM indicates acute disseminated encephalomyelitis; anti-NMDA, anti-N-methyl-d-aspartate receptor encephalitis; HHV6, human herpesvirus 6; HSV-1, herpes simplex virus type 1; VZV, varicella zoster virus.
Neuroimaging of Children With a Suspected Meningoencephalitis on Admission
| Total, n (%)Imaging at Presentation | 432 (100.0) | Proven ME | Possible ME | No ME | |
|---|---|---|---|---|---|
| Cranial ultrasonography | Performed | 60/432 (13.9) | 7/60 (11.7) | 8/60 (13.3) | 45/60 (75.0) |
| Abnormal | 13/60 (21.6) | 1/7 (14.3) | 2/8 (25.0) | 10/45 (22.2) | |
| Subdural hematoma | 7/13 (53.8) | 0/7 (0.0) | 0/8 (0.0) | 7/10 (70.0) | |
| Subdural empyema | 1/13 (7.7) | 1/7 (14.3) | 0/8 (0.0) | 0/10 (0.0) | |
| Flaring (unspecified) | 4/13 (30.8) | 0/7 (0.0) | 2/8 (25.0) | 2/10 (20.0) | |
| Dilated ventricular system | 1/13 (7.7) | 0/7 (0.0) | 0/8 (0.0) | 1/10 (10.0) | |
| CT/MRI | Performed | 73/432 (16.9) | 15/78 (21.8) | 6/78 (7.7) | 52/78 (66.7) |
| Abnormal | 35/73 (47.9) | 7/15 (46.7) | 1/6 (16.7) | 13/52 (25.0) | |
| Abscess | 1/35 (2.9) | 1/7 (14.3) | 0/6 (0.0) | 0/13 (0.0) | |
| Edema | 1/35 (2.9) | 1/7 (14.3) | 0/6 (0.0) | 0/13 (0.0) | |
| Hydrocephalus | 4/35 (11.4) | 0/7 (0.0) | 1/6 (16.7) | 3/13 (23.1) | |
| Hypodensity | 5/35 (14.3) | 2/7 (28.6) | 0/6 (0.0) | 3/13 (23.1) | |
| Subdural empyema | 2/35 (5.7) | 2/7 (28.6) | 0/6 (0.0) | 0/13 (0.0) | |
| Mastoid/sinus opacification | 8/35 (22.9) | 1/7 (14.3) | 0/6 (0.0) | 7/13 (53.8) | |
| Second CT/MRI during hospitalization | |||||
| CT/MRI | Performed | 70/432 (16.2) | 15/70 (21.4) | 6/70 (8.6) | 49/70 (70.0) |
| Abnormal | 31/70 (44.3) | 8/15 (53.3) | 2/6 (33.3) | 21/49 (42.9) | |
| Abscess | 1/31 (3.2) | 1/8 (12.5) | 0/6 (0.0) | 0/21 (0.0) | |
| Edema | 1/31 (3.2) | 1/8 (12.5) | 0/6 (0.0) | 0/21 (0.0) | |
| Hydrocephalus | 3/31 (9.7) | 0/8 (0.0) | 0/6 (0.0) | 3/21 (14.3) | |
| Hypodensity | 2/31 (6.5) | 0/8 (0.0) | 0/6 (0.0) | 2/21 (9.5) | |
| Subdural effusion | 2/31 (6.5) | 1/8 (12.5) | 0/6 (0.0) | 1/21 (4.8) | |
| Subdural empyema | 2/31 (6.5) | 2/8 (25.0) | 0/6 (0.0) | 0/21 (0.0) | |
| Mastoid/sinus opacification | 4/31 (12.9) | 1/8 (12.5) | 0/6 (0.0) | 3/21 (14.3) |
This table shows the different abnormalities identified using ultrasonography or CT/MRI and categorized based on data obtained from medical records. It is possible that multiple abnormalities were reported on the same ultrasound or CT/MRI. Data are presented as n (%).
ME indicates meningoencephalitis.
Associations Between Demographics, Clinical Characteristics, Biochemical Characteristics, Neuroimaging, Clinical Outcomes and Different Etiologic Groups
| Bacterial Meningoencephalitis | Viral Meningoencephalitis | Autoimmune Encephalitis | |
|---|---|---|---|
| Demographic characteristics | |||
| Age <1 year | 1 | 1 | 1 |
| Age between 1 and 5 years | 1.30 (0.35–8.42) | 1.15 (0.46–3.51) | 2.11 (0.04–26.90) |
| Age >5 years | 1.43 (0.38–9.24) | 2.21 (0.75–9.42) | 25.07 (2.42–1242.31) |
| Clinical characteristics | |||
| Fever | 0.96 (0.31–3.33) | 11.14 (2.78–97.15) | 0.38 (0.03–3.39) |
| Headache | 1.69 (0.17–8.63) | 1.07 (0.19–3.86) | 5.16 (0.42–46.60) |
| Irritability (age <2 years) | 1.76 (0.44–8.36) | 2.11 (0.90–5.24) | 0.00 (0.00–1.50) |
| Meningeal irritation | 0.56 (0.01–4.57) | 1.47 (0.45–4.26) | 0.00 (0.00–6.18) |
| Seizures | 1.25 (0.13–5.90) | 1.27 (0.37–3.56) | 0.00 (0.00–11.51) |
| Focal neurological symptoms | 0.00 (0.00–5.50) | 1.12 (0.12–5.00) | 12.55 (1.00–116.03) |
| Decreased consciousness | 2.01 (0.03–40.63) | 1.22 (0.19–5.51) | 0.00 (0.00–20.52) |
| Biochemical characteristics | |||
| Increased CRP | 5.24 (1.43–28.90) | 1.07 (0.51–2.25) | 0.35 (0.01–4.44) |
| Increased WBC (blood) | 3.77 (0.99–12.28) | 1.05 (0.26–3.18) | 0.00 (0.00–6.82) |
| Increased WBC (CSF) | 19.69 (4.16–186.51) | 2.67 (1.13–6.17) | 4.81 (0.54–58.44) |
| Increased total protein (CSF) | 14.75 (3.99–60.99) | 0.52 (0.06–2.21) | 1.88 (0.04–19.66) |
| Decreased CSF/blood glucose ratio | 3.97 (0.92–23.95) | 3.04 (1.09–8.97) | 0.70 (0.01–13.58) |
| Neuroimaging | |||
| Abnormalities on cranial US | 0.00 (0.00–7.35) | 0.00 (0.00–3.16) | 0.00 (0.00–27.51) |
| Abnormalities on CT/MRI | 0.70 (0.02–4.77) | 1.41 (0.34–4.37) | 18.20 (2.01–224.76) |
| Outcomes | |||
| Death | 0.00 (0.00–10.21) | 2.64 (0.26–13.97) | 0.00 (0.00–37.85) |
| Neurological deficits on discharge | 4.43 (0.44–22.82) | 0.00 (0.00–3.16) | 14.49 (1.22–111.61) |
| ICU admission | 1.63 (0.29–6.14) | 1.18 (0.34–3.26) | 5.11 (0.42–45.75) |
| Circulatory support | 7.08 (2.11–22.83) | 1.06 (0.26–3.25) | 0.00 (0.00–6.90) |
| Mechanical ventilation | 2.95 (0.65–10.56) | 1.02 (0.25–3.13) | 5.29 (0.43–47.54) |
This table shows the univariate OR of a binary logistic regression analysis, evaluating the associations between clinical characteristics, biochemical characteristics, abnormalities on neuroimaging, clinical outcomes and different etiologic groups. Data are reported as OR (95% CI).
Significant association.
US indicates ultrasound.